Britain's "one belt, one road" market expands, and central and Eastern Europe needs China medicine.

Source: pharmaceutical economic daily, July 1, 2016, recently, during the 16th world pharmaceutical raw materials China exhibition, the 2nd China CEEC health ministers forum health industry cooperation sub forum and the 7th China and world pharmaceutical entrepreneurs summit were held at the same time This forum focuses on cooperation opportunities between China and central and Eastern Europe in health industry Xu Ming, vice president of China Chamber of Commerce for the import and export of medical and health care products, pointed out: "although central and Eastern European countries are far away from China, we have many similarities in the process of social and economic transformation, especially the improvement of the medical security system, and we are facing a common challenge, that is, how to improve the payment level and provide high cost-effective products for the people." According to Xu Ming, ginautas barcys, director of Lithuanian drug administration, said: "central and Eastern European countries and China need more cooperation and more safe drugs, and at the same time, budget and sustainable development of medical and health industry must be considered." One belt, one road strategy will be implemented in China and the Chinese pharmaceutical companies will enter the central and Eastern European market In the face of new emerging markets, industry insiders agree that the advantage of Chinese pharmaceutical products is high cost performance Tao Jianhong, deputy director of CFDA South pharmaceutical economics research institute, pointed out: "in the international market procurement, overseas buyers have a greater sense of identity with the quality standards of Chinese pharmaceutical products, and the price advantage of local products is still in place However, purchasers still have strong demands for improving the quality of Chinese products " At this meeting, Jan Ruzicka, Czech special envoy for health, said:“ In EU countries, there are many very good innovative drugs, but central and Eastern Europe are different We don't have them These drugs are made in China or in other countries and regions We hope to directly trade with China and directly reduce costs We can help Chinese enterprises carry out GMP Certification, in our country, many small and medium-sized pharmaceutical enterprises are looking for cooperation opportunities After entering the Czech Republic, Chinese enterprises can distribute through joint venture and investment, so as to open the market of EU Member States " According to á ges f é NYI feket é n é, senior counsellor of the Ministry of economy of Hungary, Chinese herbal medicines are very important for Hungary Many Chinese herbal medicines can be planted in Hungary, with the annual growth rate of 7% - 10% In the future, it is hoped that the two countries will have an opportunity to further cooperate on raw materials of Chinese herbal medicines Facing the needs of central and Eastern European countries for cost-effective products, Xu Ming thought: "it's very difficult for us to create a relative balance between fairness and efficiency We can't completely solve the problem by relying on the market mechanism The government must intervene when appropriate, so as to achieve a relative balance between fairness and efficiency Therefore, we must establish an evaluation system to judge whether drugs can truly achieve the relative balance between fairness and efficiency In the evaluation system, we need to consider many factors including commercial, clinical, regulatory and social factors to achieve the relative balance between fairness and efficiency " For Chinese enterprises to enter the market of central and Eastern Europe, many pharmaceutical enterprises present at the meeting have their own views According to Shen Yaping, deputy general manager of Hengrui pharmaceutical, "the first step for us to understand the local market through partners, whether we are in the European and American market or in the Japanese market, and to be in the central and Eastern Europe market, we hope to select partners first, with the help of partners, we can achieve half the result." Speaking of the "one belt, one road" concept, the central and Eastern European market, Luo Shizhong, general manager of the Asia International Trade Co., Ltd., said: "the concept of central and Eastern Europe is more complicated Some countries are close to the European Union, the regulations are very strict, and some countries are similar to Russia, and the regulations are relatively loose However, what needs to be noticed by Chinese pharmaceutical companies is that central and Eastern European countries need high-quality generic drugs We cannot provide products of low quality because some countries are not regulatory markets " After years of internationalization of R & D cooperation opportunities, domestic export enterprises have summed up a lot of experience Li can, general manager of Sinopharm international, thinks:“ We have been discussing how to let China's pharmaceutical products go out After years of exploration, we have found the path of industrial chain export, that is to form two closed loops from China's export to local sales, including both export and import Therefore, I personally believe that 16 + 1 is very important for the development of central and Eastern Europe " R & D cooperation seems to be a bright spot that has not appeared in foreign trade cooperation in the past Jan Ruzicka said: "innovation is very important We can also make cooperative investment in R & D the Czech Republic has a very large demand for bulk APIs Through comprehensive solutions, we can bring higher value and profits to both sides Czech pharmaceutical companies predict the disease development mode of patients through gene detection and lifestyle research and analysis of Alzheimer's disease patients The accuracy has reached more than 80% It is a simple and economic way of early health intervention This project has cooperated with many famous hospitals in the world, and we hope to cooperate with China " In contrast, Hungary pays attention to biopharmaceuticals According to á nges f é NYI feket é n é, "in Hungary, the pharmaceutical industry accounts for a large proportion of the economy, while 40% of the employees of pharmaceutical enterprises have very high degrees Hungary has a strong momentum in the development of biopharmaceuticals, and many universities are involved in the research and development of new drugs We hope that Chinese enterprises can also carry out R & D cooperation with us Despite the slowdown of China's economic growth, the market growth is still stable For pharmaceutical companies in central and Eastern Europe, the prospect of entering the Chinese market is very good, and there are also good opportunities for Chinese companies to invest in central and Eastern Europe " "We have been introducing the latest technology to produce the latest products," said Jiang Hua, vice president of green leaf pharmaceutical, a domestic R & D pharmaceutical company From this point of view, we also hope to further cooperate with central and Eastern European countries and finally sell our products in China "